PEG-interferon alfa-2b

BIOLOGICAL15 trials

Conditions

Fallopian Tube CancerGliomaHead and Neck CancerHepatitis C, ChronicIntraocular MelanomaKidney CancerLymphomaMelanoma (Skin)

Phase 1

Temozolomide Plus PEG-Interferon Alfa-2B in Treating Patients With Advanced Solid Tumors

CompletedNCT00014261

Dartmouth-Hitchcock Medical CenterUnspecified Adult Solid Tumor, Protocol Specific

Start: 2000-10-31End: 2002-11-30Updated: 2018-03-30

PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer

TerminatedNCT00085384

M.D. Anderson Cancer CenterFallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer

Start: 2002-07-31End: 2007-04-30Updated: 2012-08-02

PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer

TerminatedNCT00589550

Thomas OlenckiKidney Cancer

Start: 2008-02-29End: 2009-01-31Updated: 2015-06-08

Phase 2

Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas

CompletedNCT00047879

National Cancer Institute (NCI)Glioma

Start: 2002-10-31End: 2009-06-30Updated: 2011-10-26

PEG-Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer

CompletedNCT00045279

Memorial Sloan Kettering Cancer CenterKidney Cancer

Start: 2002-04-30End: 2005-09-30Updated: 2013-06-05

PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma

CompletedNCT00049530

Eastern Cooperative Oncology GroupMelanoma (Skin)

Start: 2004-01-13End: 2014-06-30Updated: 2023-06-29

Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors

CompletedNCT00055809

National Cancer Institute (NCI)Metastatic Gastrointestinal Carcinoid Tumor, Recurrent Gastrointestinal Carcinoid Tumor, Regional Gastrointestinal Carcinoid Tumor

Start: 2003-01-31Updated: 2013-01-23

PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer

TerminatedNCT00090870

Medical University of South CarolinaKidney Cancer

Start: 2002-04-30End: 2010-03-31Updated: 2018-07-12

PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma

CompletedNCT00238329

Barbara Ann Karmanos Cancer InstituteIntraocular Melanoma, Melanoma (Skin)

Start: 2001-01-31End: 2007-06-30Target: 32Updated: 2013-04-08

PEG-interferon Alfa-2b in Treating Patients With Stage II, Stage III, or Stage IV Head and Neck Cancer That Can Be Removed By Surgery

CompletedNCT00276523

M.D. Anderson Cancer CenterHead and Neck Cancer

Start: 2004-02-29End: 2006-03-31Updated: 2012-10-31

Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer

TerminatedNCT00467077

California Cancer ConsortiumKidney Cancer

Start: 2004-09-30End: 2011-03-31Updated: 2017-03-17

Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003)

CompletedNCT01353911

Merck Sharp & Dohme LLCHepatitis C, Chronic

Start: 2011-06-27End: 2015-03-10Updated: 2024-05-22

Phase 3

Triple Therapy With Peg-Interferon Alfa-2b/Ribavirin Plus Amantadine Compared to Standard Peg-Interferon Alfa-2b/Ribavirin for Previous Hepatitis C Virus (HCV) Non Responders

TerminatedNCT00122629

French National Agency for Research on AIDS and Viral HepatitisHepatitis C, Chronic

Start: 2000-10-31End: 2003-05-31Target: 405Updated: 2005-07-29

Short Duration Versus Standard Response-Guided Therapy With Boceprevir Combined With PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Asian Participants With Chronic HCV Genotype 1 (MK-3034-107)

CompletedNCT01945294

Merck Sharp & Dohme LLCHepatitis C, Chronic

Start: 2013-10-10End: 2015-11-04Updated: 2018-07-12

Phase 4

Zidovudine, Interferon Alfa-2b, PEG-Interferon Alfa-2b in Patients With HTLV-I Associated Adult T-Cell Leukemia/Lymphoma

TerminatedNCT00854581

University of MiamiLymphoma, Precancerous/Nonmalignant Condition

Start: 2007-11-30End: 2011-11-30Updated: 2018-04-17

Related Papers

Virologic Resistance Analysis From a Phase 2 Study of MK-5172 Combined With Pegylated Interferon/Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection

Clinical Infectious Diseases2014-09-2836 citations

The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis.

2014-04-1230 citations